Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Sep;25(3):288-291.
doi: 10.1111/jns.12406. Epub 2020 Aug 26.

Reliability of the Charcot-Marie-Tooth functional outcome measure

Affiliations
Multicenter Study

Reliability of the Charcot-Marie-Tooth functional outcome measure

Paula Bray et al. J Peripher Nerv Syst. 2020 Sep.

Abstract

The CMT-FOM is a 13-item clinical outcome assessment (COA) that measures physical ability in adults with Charcot-Marie-Tooth disease (CMT). Test-retest reliability, internal consistency and convergent validity have been established for the CMT-FOM. This current study sought to establish inter-rater reliability. Following an in-person training of six international clinical evaluators we recruited 10 participants with genetically diagnosed CMT1A, (aged 18-74 years, 6 female). Participants were evaluated using the CMT-FOM over 2 days. Participants were given at least a 3 hour rest between evaluations, and were assessed twice each day. Following the provision of training by master trainers, all 13 items of the CMT-FOM exhibited excellent inter-rater reliability for raw scores (ICC1,1 0.825-0.989) and z-scores (ICC1,1 0.762-0.969). Reliability of the CMT-FOM total score was excellent (ICC1,1 0.983, 95% CI 0.958-0.995). The CMT-FOM is a reliable COA used by clinical evaluators internationally. The next steps are to establish further validation through psychometric evaluation of the CMT-FOM in the Accelerate Clinical Trials in CMT (ACT-CMT) study.

Keywords: clinical evaluation; clinical outcome assessment; functional measurement; measurement.

PubMed Disclaimer

References

    1. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth’s disease. Clinical genetics. 1974;6:98–118. - PubMed
    1. Fridman V, Reilly M. Inherited neuropathies. Paper presented at: Seminars in neurology 2015. - PubMed
    1. Reilly MM, Murphy SM, Laura M. Charcot-Marie-tooth disease. Journal of the peripheral nervous system. 2011;16:1–14. - PubMed
    1. Zhao HT, Damle S, Ikeda-Lee K, et al. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. The Journal of clinical investigation. 2018;128:359–368. - PMC - PubMed
    1. Bums J, Ouvrier R, Estilow T, et al. Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability. Annals of Neurology. 2012;71:642–652. - PMC - PubMed

Publication types